AN2 Therapeutics Ownership | Who Owns AN2 Therapeutics?


OverviewFinancialsChart

AN2 Therapeutics Ownership Summary


AN2 Therapeutics is owned by 48.69% institutional investors, 19.69% insiders, and 31.62% retail investors. Bml capital management is the largest institutional shareholder, holding 19.27% of ANTX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.51% of its assets in AN2 Therapeutics shares.

ANTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAN2 Therapeutics48.69%19.69%31.62%
SectorHealthcare Stocks 57.43%9.41%33.16%
IndustryBiotech Stocks 69.02%8.92%22.06%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bml capital management5.75M19.27%$7.93M
Citadel advisors1.55M5.22%$3.34M
Almitas capital1.31M4.40%$1.81M
Vanguard group1.04M3.47%$1.43M
Pfizer715.29K2.40%$987.11K
Renaissance579.77K1.94%$800.09K
Two sigma advisers, lp528.30K1.77%$729.05K
Bank of montreal /can/422.08K1.41%$582.47K
Two sigma investments, lp400.33K1.34%$552.46K
Bank of nova scotia394.87K1.32%$544.92K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bml capital management5.75M4.93%$7.93M
Aldebaran capital343.68K0.45%$474.28K
Almitas capital1.31M0.40%$1.81M
Stonepine capital management196.73K0.22%$271.49K
Pfizer715.29K0.04%$987.11K
Marquette asset management83.21K0.02%$114.83K
Bridgeway capital management162.20K0.01%$223.84K
Xtx topco34.18K0.00%$47.17K
Two sigma advisers, lp528.30K0.00%$729.05K
Renaissance579.77K0.00%$800.09K

Top Buyers

HolderShares% AssetsChange
Almitas capital1.31M0.40%1.31M
Pfizer715.29K0.04%715.29K
Bank of montreal /can/422.08K0.00%422.08K
Two sigma advisers, lp528.30K0.00%407.40K
Bank of nova scotia394.87K0.00%394.87K

Top Sellers

HolderShares% AssetsChange
Octagon capital advisors lp---3.22M
Frazier life sciences management---2.09M
Ra capital management---2.00M
Tcg crossover management---1.56M
Bvf inc/il---1.24M

New Positions

HolderShares% AssetsChangeValue
Almitas capital1.31M0.40%1.31M$1.81M
Pfizer715.29K0.04%715.29K$987.11K
Bank of montreal /can/422.08K0.00%422.08K$582.47K
Bank of nova scotia394.87K0.00%394.87K$544.92K
Stonepine capital management196.73K0.22%196.73K$271.49K

Sold Out

HolderChange
Wells fargo & company/mn-128.00
Fmr-300.00
California state teachers retirement system-9.25K
Clear street markets-10.00K
Atom investors lp-11.90K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20243719.35%14,528,9307.52%482.37%2450.00%7-
Sep 30, 202431-31.11%13,513,224-30.40%451.06%16-20.00%7-46.15%
Jun 30, 202445-16.67%19,415,9093.64%651.04%20-35.48%13-18.75%
Mar 31, 2024545.88%18,733,564-8.13%791.26%31-3.13%1660.00%
Dec 31, 20235137.84%20,391,5032.31%790.76%3223.08%1025.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv749.42K2.51%-
Vanguard Institutional Extnd Mkt Idx Tr261.93K0.88%-
Bridgeway Ultra-Small Company Market161.30K0.54%-
Fidelity Extended Market Index117.53K0.39%-947.00
iShares Micro-Cap ETF35.21K0.12%-
BlackRock Extended Equity Market K33.77K0.11%-14.00
Extended Equity Market Fund K33.31K0.11%-459.00
Bridgeway Ultra-Small Company33.20K0.11%33.20K
Fidelity Total Market Index31.26K0.10%-
Fidelity Series Total Market Index28.46K0.10%-

Recent Insider Transactions


DateNameRoleActivityValue
Jan 03, 2025Day Lucy Chief Financial OfficerSell$3.97K
Jan 03, 2025Chanda Sanjay Chief Development OfficerSell$3.97K
Jan 03, 2025Prior Stephen David Chief Strategy OfficerSell$2.72K
Jan 03, 2025Eizen Joshua M See RemarksSell$12.96K
Dec 10, 2024Readnour Robin Shane-Buy$7.46K

Insider Transactions Trends


DateBuySell
2025 Q1-4
2024 Q418-
2024 Q312
2024 Q2--
2024 Q1-12

ANTX Ownership FAQ


Who Owns AN2 Therapeutics?

AN2 Therapeutics shareholders are primarily institutional investors at 48.69%, followed by 19.69% insiders and 31.62% retail investors. The average institutional ownership in AN2 Therapeutics's industry, Biotech Stocks , is 69.02%, which AN2 Therapeutics falls below.

Who owns the most shares of AN2 Therapeutics?

AN2 Therapeutics’s largest shareholders are Bml capital management (5.75M shares, 19.27%), Citadel advisors (1.55M shares, 5.22%), and Almitas capital (1.31M shares, 4.40%). Together, they hold 28.89% of AN2 Therapeutics’s total shares outstanding.

Does Blackrock own AN2 Therapeutics?

BlackRock is not among the top 10 institutional shareholders of AN2 Therapeutics.

Who is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested?

Bml capital management is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.93% of its assets in 5.75M AN2 Therapeutics shares, valued at 7.93M$.

Who is the top mutual fund holder of AN2 Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of AN2 Therapeutics shares, with 2.51% of its total shares outstanding invested in 749.42K AN2 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools